In The Know-May 2026

May 2026
Pdf Summary
This monthly “Ed’s List” roundup highlights recent gynecologic oncology and related women’s health literature of significance, with emphasis on ovarian, endometrial, cervical, and vulvar disease.<br /><br />Key ovarian cancer findings include several advances in tumor biology and treatment resistance. A Science Translational Medicine study showed that genomic instability can drive POSTN myofibroblasts through a STING–WNT axis, creating immunosuppression and PARP inhibitor resistance; blocking POSTN improved T-cell activity and enhanced PARPi response in models. Another study found ascites protects ovarian cancer cells from ferroptosis and supports peritoneal growth, partly by altering lipid and iron handling, with fibrates reversing some of these effects. In Immunity, tumor-draining lymph nodes in high-grade serous ovarian cancer lacked germinal centers but contained tumor-reactive memory B cells clonally linked to intratumoral B cells. Endocrinology reported that ovarian cancer cell glucocorticoid receptor signaling promotes an immunosuppressive microenvironment by increasing MDSC recruitment, suggesting GR modulation may improve immunotherapy. JCO Precision Oncology showed that ovarian cancers with homozygous loss of homologous recombination repair genes may derive substantial benefit from PARP inhibitors, underscoring the need for sequencing assays to report this alteration class.<br /><br />For endometrial cancer, Cancer Research identified NSD1-mediated methylation of PPARγ as a tumor-suppressive pathway that increases PTEN, restrains glycolysis, and reduces invasion; NSD1 loss reverses these effects and may be therapeutically targetable.<br /><br />Other clinically relevant studies included a large Taiwanese cohort showing tamoxifen use in premenopausal women with breast cancer increased uterine disease risk, including endometrial cancer, supporting surveillance. In vulvar disease, lichen sclerosus was strongly associated with vulvar dysplasia and malignancy, while clobetasol appeared protective.<br /><br />Broader oncology studies emphasized that genomically matched therapy improves survival only when supported by prospective clinical trial evidence, not merely preclinical or repurposed rationale. Preventive care studies highlighted major gaps in HPV vaccination and multi-cancer screening, and a Puerto Rico study documented divergent cervical cancer trends by age, with declines in younger women but increases among ages 35–49.
Keywords
ovarian cancer
gynecologic oncology
PARP inhibitor resistance
tumor microenvironment
ferroptosis
endometrial cancer
tamoxifen uterine risk
vulvar dysplasia
HPV vaccination
cervical cancer trends